poractant alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5148	129069-19-8

Description:

Molecule	Description
Synonyms: poractant alfa curosurf	Endogenous pulmonary surfactant (isolated from porcine lungs) reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in Respiratory Distress Syndrome (RDS) characterized by poor lung expansion, inadequate gas exchange, and a gradual collapse of the lungs (atelectasis). Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

poractant alfa
curosurf

Endogenous pulmonary surfactant (isolated from porcine lungs) reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in Respiratory Distress Syndrome (RDS) characterized by poor lung expansion, inadequate gas exchange, and a gradual collapse of the lungs (atelectasis).

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 18, 1999	FDA	CHIESI USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neonatal hypoxia	245.23	165.02	26	64	609	63488323

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neonatal hypoxia	371.91	99.02	43	217	364	34956307

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000000079	Surfactant Activity
FDA PE	N0000008294	Alveolar Surface Tension Reduction
MeSH PA	D011663	Pulmonary Surfactants
MeSH PA	D019141	Respiratory System Agents
FDA EPC	N0000175778	Surfactant

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Respiratory distress syndrome in the newborn	indication	46775006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
KE3U2023NP	UNII
4021204	VANDF
C0771648	UMLSCUI
CHEMBL1201622	ChEMBL_ID
D08402	KEGG_DRUG
DB09113	DRUGBANK_ID
236381	RXNORM
31530	MMSL
8499	MMSL
d04496	MMSL
005782	NDDF
116075008	SNOMEDCT_US
386999001	SNOMEDCT_US
C068291	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Curosurf	HUMAN PRESCRIPTION DRUG LABEL	1	10122-510	SUSPENSION	80 mg	ENDOTRACHEAL	BLA	19 sections
Curosurf	HUMAN PRESCRIPTION DRUG LABEL	1	10122-510	SUSPENSION	80 mg	ENDOTRACHEAL	BLA	19 sections